Geode Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.01B | Buy |
2,607,732
+88,192
| +4% | +$67.5M | 0.12% | 133 |
|
|
2025
Q4 | $1.94B | Sell |
2,519,540
-16,358
| -0.6% | -$11.1M | 0.12% | 133 |
|
|
2025
Q3 | $1.42B | Buy |
2,535,898
+70,844
| +3% | +$40.1M | 0.09% | 183 |
|
|
2025
Q2 | $1.29B | Sell |
2,465,054
-4,531
| -0.2% | -$2.53M | 0.09% | 189 |
|
|
2025
Q1 | $1.56B | Buy |
2,469,585
+41,955
| +2% | +$28.9M | 0.12% | 141 |
|
|
2024
Q4 | $1.73B | Buy |
2,427,630
+155,369
| +7% | +$130M | 0.13% | 122 |
|
|
2024
Q3 | $2.38B | Sell |
2,272,261
-143,089
| -6% | -$159M | 0.19% | 89 |
|
|
2024
Q2 | $2.53B | Buy |
2,415,350
+38,759
| +2% | +$37.6M | 0.22% | 76 |
|
|
2024
Q1 | $2.28B | Buy |
2,376,591
+22,374
| +1% | +$21.3M | 0.21% | 82 |
|
|
2023
Q4 | $2.06B | Buy |
2,354,217
+34,231
| +1% | +$28.2M | 0.22% | 82 |
|
|
2023
Q3 | $1.91B | Buy |
2,319,986
+38,857
| +2% | +$30.5M | 0.23% | 79 |
|
|
2023
Q2 | $1.64B | Buy |
2,281,129
+63,136
| +3% | +$48.7M | 0.19% | 94 |
|
|
2023
Q1 | $1.82B | Buy |
2,217,993
+10,003
| +0.5% | +$7.54M | 0.24% | 80 |
|
|
2022
Q4 | $1.59B | Sell |
2,207,990
-32,123
| -1% | -$23.7M | 0.22% | 87 |
|
|
2022
Q3 | $1.54B | Buy |
2,240,113
+26,009
| +1% | +$16.4M | 0.23% | 76 |
|
|
2022
Q2 | $1.31B | Buy |
2,214,104
+121,333
| +6% | +$78.9M | 0.19% | 95 |
|
|
2022
Q1 | $1.46B | Buy |
2,092,771
+115,469
| +6% | +$73.1M | 0.18% | 98 |
|
|
2021
Q4 | $1.25B | Buy |
1,977,302
+237,090
| +14% | +$146M | 0.15% | 115 |
|
|
2021
Q3 | $1.05B | Buy |
1,740,212
+32,212
| +2% | +$20M | 0.14% | 124 |
|
|
2021
Q2 | $951M | Buy |
1,708,000
+97,810
| +6% | +$49.6M | 0.13% | 131 |
|
|
2021
Q1 | $760M | Buy |
1,610,190
+23,271
| +1% | +$11.3M | 0.12% | 151 |
|
|
2020
Q4 | $765M | Sell |
1,586,919
-170,067
| -10% | -$91.8M | 0.13% | 136 |
|
|
2020
Q3 | $982M | Buy |
1,756,986
+235,853
| +16% | +$143M | 0.19% | 96 |
|
|
2020
Q2 | $947M | Buy |
1,521,133
+188,616
| +14% | +$107M | 0.2% | 92 |
|
|
2020
Q1 | $649M | Buy |
1,332,517
+65,789
| +5% | +$27.1M | 0.17% | 121 |
|
|
2019
Q4 | $475M | Buy |
1,266,728
+25,165
| +2% | +$8.47M | 0.1% | 200 |
|
|
2019
Q3 | $344M | Buy |
1,241,563
+81,002
| +7% | +$24M | 0.08% | 253 |
|
|
2019
Q2 | $363M | Buy |
1,160,561
+62,713
| +6% | +$20.9M | 0.09% | 231 |
|
|
2019
Q1 | $450M | Buy |
1,097,848
+19,395
| +2% | +$7.99M | 0.12% | 179 |
|
|
2018
Q4 | $402M | Buy |
1,078,453
+78,143
| +8% | +$28.6M | 0.12% | 161 |
|
|
2018
Q3 | $403M | Buy |
1,000,310
+29,493
| +3% | +$11.2M | 0.11% | 169 |
|
|
2018
Q2 | $334M | Buy |
970,817
+34,841
| +4% | +$10.9M | 0.1% | 193 |
|
|
2018
Q1 | $322M | Buy |
935,976
+55,495
| +6% | +$19.3M | 0.1% | 193 |
|
|
2017
Q4 | $330M | Buy |
880,481
+30,581
| +4% | +$12.4M | 0.11% | 183 |
|
|
2017
Q3 | $379M | Buy |
849,900
+20,395
| +2% | +$9.7M | 0.14% | 138 |
|
|
2017
Q2 | $407M | Buy |
829,505
+97,071
| +13% | +$42.5M | 0.16% | 122 |
|
|
2017
Q1 | $283M | Buy |
732,434
+62,796
| +9% | +$23.3M | 0.12% | 178 |
|
|
2016
Q4 | $246M | Buy |
669,638
+31,097
| +5% | +$11.8M | 0.11% | 176 |
|
|
2016
Q3 | $256M | Buy |
638,541
+1,979
| +0.3% | +$794K | 0.13% | 155 |
|
|
2016
Q2 | $222M | Sell |
636,562
-4,248
| -0.7% | -$1.64M | 0.12% | 167 |
|
|
2016
Q1 | $231K | Buy |
640,810
+14,289
| +2% | +$5.89M | 0.12% | 156 |
|
|
2015
Q4 | $339M | Buy |
626,521
+5,085
| +0.8% | +$2.76M | 0.19% | 104 |
|
|
2015
Q3 | $288M | Buy |
621,436
+20,244
| +3% | +$10.9M | 0.18% | 114 |
|
|
2015
Q2 | $306M | Buy |
601,192
+18,970
| +3% | +$9.26M | 0.17% | 115 |
|
|
2015
Q1 | $262M | Buy |
582,222
+19,294
| +3% | +$8.18M | 0.15% | 134 |
|
|
2014
Q4 | $231M | Buy |
562,928
+24,929
| +5% | +$9.8M | 0.14% | 149 |
|
|
2014
Q3 | $194M | Sell |
537,999
-41,519
| -7% | -$13.9M | 0.13% | 161 |
|
|
2014
Q2 | $164M | Buy |
579,518
+3,446
| +0.6% | +$1.02M | 0.11% | 195 |
|
|
2014
Q1 | $173M | Buy |
576,072
+4,195
| +0.7% | +$1.29M | 0.12% | 179 |
|
|
2013
Q4 | $157M | Buy |
571,877
+21,813
| +4% | +$6.27M | 0.11% | 189 |
|
|
2013
Q3 | $172M | Buy |
550,064
+30,553
| +6% | +$8.04M | 0.14% | 147 |
|
|
2013
Q2 | $117M | Buy |
+519,511
| New | +$121M | 0.1% | 204 |
|
Other funds holding REGN
VCM
N
Geode Capital Management's REGN Position: Q1 2026 in Review
Geode Capital Management increased its Regeneron Pharmaceuticals (REGN) stake by 3.5% in Q1 2026, buying an estimated $67.5M and bringing the position to 2,607,732 shares worth $2.01B. The position accounts for 0.12% of the portfolio, ranked #133.
Geode Capital Management first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.53B in Q2 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Geode Capital Management held 2,607,732 shares of Regeneron Pharmaceuticals worth $2.01B as of Q1 2026.
- Geode Capital Management bought 88,192 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $67.5M.
- Regeneron Pharmaceuticals made up 0.12% of Geode Capital Management's portfolio in Q1 2026, its #133 holding.
- Geode Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Geode Capital Management's Regeneron Pharmaceuticals position peaked at $2.53B in Q2 2024.
- 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.